Joseph Barsuglia
Clinical and research psychologist specializing in psychedelic medicine and alternative healthcare
Data updated
Research Footprint
Joseph Barsuglia appears in 11 tracked papers (2017–2026), most studied alongside Ibogaine, 5-MeO-DMT and Psilocybin, across Substance Use Disorders (SUD), Anxiety Disorders and Depressive Disorders.
Most-cited paper: 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety (139 citations).
Frequent co-authors: Alan Davis, Martin Polanco and Rafaelle Lancelotta.
Publication Landscape
How the 11 papers Blossom tracks for Joseph Barsuglia line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Joseph Barsuglia's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 11 of 11 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Joseph Barsuglia publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Joseph Barsuglia publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Joseph P. Barsuglia is a clinical researcher working at the intersection of psychedelic medicine and addiction/psychiatric care. His recent contributions emphasise pragmatic, real‑world investigations—ranging from longitudinal case studies of 5‑MeO‑DMT for post‑traumatic stress disorder and suicidality to naturalistic group‑setting evaluations that report unintended improvements in anxiety and depression. Barsuglia has also contributed to case reports and SPECT imaging studies that examine sequential administration strategies combining ibogaine and 5‑MeO‑DMT for alcohol use disorder, and he has authored mixed‑method analyses of persisting effects following ibogaine detoxification.
Key Impact
Notable for conducting real-world and clinical case studies on 5‑MeO‑DMT and ibogaine, exploring their therapeutic potential for PTSD, mood disorders and substance use disorders.
Collaboration Network
9 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Joseph Barsuglia's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Joseph Barsuglia is associated with.
HU Azores & Ancestral Heart
Psychedelic-adjacent facilitation and stewardship initiative linked to plant-medicine retreat programming and indigenous reciprocity work.
View stakeholder →The Mission Within
The Mission Within is a veteran-focused program associated with ibogaine and 5-MeO-DMT retreat work in Mexico, with preparation and integration support around the medicine component. Its public messaging centers on healing, community, and reducing veteran suicide.
View stakeholder →Beond Ibogaine
Beond Ibogaine is a specialized ibogaine treatment clinic offering medically supervised care programs focused on addiction, trauma, and recovery pathways.
View stakeholder →